在早期和晚期激素受体阳性,HER2阴性乳腺癌中抑制CDK4/6
Sudha Yarlagadda1, Matheus de Oliveira Andrade2, Rita Nanda1,3
1Department of Medicine, Section of Hematology/Oncology, The University of Chicago, Chicago, IL, USA.
循环素依赖性激酶4和6 (CDK4/6) 抑制剂对于治疗晚期和高风险的早期激素受体阳性,HER2阴性乳腺癌至关重要. 目前正在进行的研究旨在通过新的组合来改善结果,尽管仍需要预测生物标志物.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 循环素依赖性激酶4和6 (CDK4/6) 抑制剂是激素受体阳性,HER2阴性 (HR+/HER2-) 晚期乳腺癌的基石疗法.
- 这些抑制剂,包括abemaciclib和ribociclib,也已被批准用于高风险的早期HR+/HER2乳腺癌.
研究的目的:
- 对HR+/HER2-乳腺癌中CDK4/6抑制的科学基础进行审查.
- 总结关键的临床试验导致监管批准.
- 讨论正在进行的试验,探索新的组合,以改善患者的治疗结果.
主要方法:
- 从2000年1月1日到2024年12月31日,PubMed MEDLINE的综合文献审查.
- 对CDK4/6抑制剂的临床试验数据和监管批准的分析.
- 综合关于新型治疗组合的当前研究.
主要成果:
- CDK4/6抑制剂是管理高级和早期HR+/HER2-乳腺癌的组成部分.
- 对CDK4/6抑制剂的益处进行预测的生物标志物仍然难以捉摸.
- 目前,临床和病理特征是早期患者选择的关键.
结论:
- CDK4/6抑制剂是HR+/HER2-乳腺癌的已知治疗方法.
- 进一步的研究重点是新的组合来提高疗效.
- 确定预测性生物标志物仍然是未来研究的关键领域.
更多相关视频
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
相关概念视频
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Negative Regulator Molecules
